Switzerland (CH)

TGFβ PROMOTES FIBROSIS BY MYST1-DEPENDENT EPIGENETIC REGULATION OF AUTOPHAGY (2018) Zehender A, Lin NY, Stefanica A, Chen CW, Soarel A, Wohlfahrt T, Reuber S, et al. Conference contribution Secukinumab Efficacy in Psoriatic Arthritis: Individual Patient Meta-Analysis of Four Phase 3 Trials in 2049 Patients (2018) Gottlieb AB, Mease PJ, Kirkham B, Nash P, Balsa A, Combe B, Rech J, et al. Conference contribution SECUKINUMAB EFFICACY IN PSORIATIC ARTHRITIS PATIENTS WITH OR WITHOUT ENTHESITIS AT BASELINE - POOLED ANALYSIS FROM TWO PHASE-III TRIALS OVER 2 YEARS (2018) Wallman JK, Schett G, Mcinnes IB, Quebe-Fehling E, Rasouliyan L, Pricop L, Fasth AE, Gaillez C Conference contribution Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis: Long-Term (4-Year) Data from a Phase 3 Study (2018) Mcinnes IB, Kivitz AJ, Nash P, Rahman P, Rech J, Kirkham B, Navarra SV, et al. Conference contribution Secukinumab Provides Sustained Improvements in the Signs and Symptoms in Psoriatic Arthritis: Final 5 Year Efficacy and Safety Results from a Phase 3 Trial (2018) Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, et al. Conference contribution SECUKINUMAB EFFICACY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: META-ANALYSIS OF 4 PHASE 3 TRIALS (2018) Mease P, Kirkham B, Nash P, Balsa A, Combe B, Rech J, Martin R, et al. Conference contribution MICRORNA-125B REGULATES APOPTOSIS IN SYSTEMIC SCLEROSIS (2018) Kozlova A, Pachera E, Maurer B, Juengel A, Distler J, Kania G, Distler O Conference contribution RITUXIMAB IN SYSTEMIC SCLEROSIS : SAFETY AND EFFICACY DATA FROM THE EUSTAR NETWORK (2018) Elhai M, Distler O, Smith V, Matucci-Cerinic M, Alegre-Sancho JJ, Truchetet ME, Braun-Moscovici Y, et al. Conference contribution Racial differences in SSc disease presentation: a European scleroderma trials and research group (EUSTAR) study (2018) Jaeger VK, Siegert E, Hachulla E, Airo P, Valentini G, Matucci-Cerinic M, Scorza R, et al. Conference contribution Orphan Nuclear Receptor Ror alpha Is a Key Regulator of Tgf beta- and WNT-Signaling in Fibrotic Diseases (2018) Kagwiria R, Liang R, Matei AE, Sihler N, Chen CW, Burris T, Distler O, et al. Conference contribution